secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2023-03-06T23:59:59+00:00
Accession:  0001193125-23-061524
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase Therapeutics awards stock options to CEO and CFO with performance vesting tied to Phase 2a study
--------------------------------------------------------------------------------

- CEO Milton H. Werner granted options for 315,000 shares at $0.7390; 105,000 subject to performance vesting.
- CFO Joseph Frattaroli granted options for 135,000 shares at $0.7390; 45,000 subject to performance vesting.
- Performance milestones tied to completion and release of IKT-148009 Phase 2a study in Parkinson's disease.
- Remaining options subject to time vesting under 2020 Equity Incentive Plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312523061524/0001193125-23-061524-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312523061524/d410993d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-061524

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer